Just over a year after approval, AstraZeneca’s Calquence is giving J&J and AbbVie’s Imbruvica a run for its money in mantle cell lymphoma. But the British drugmaker doesn’t want to stop there. It’s eyeing a bigger market: chronic lymphocytic leukemia.
More: AstraZeneca's Calquence found success in lymphoma. Will CLL follow?